These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24239593)

  • 1. Genetic dissection of the psychotomimetic effects of cannabinoid exposure.
    O'Tuathaigh CM; Gantois I; Waddington JL
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():33-40. PubMed ID: 24239593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications.
    Pelayo-Terán JM; Pérez-Iglesias R; Mata I; Carrasco-Marín E; Vázquez-Barquero JL; Crespo-Facorro B
    Psychiatry Res; 2010 Oct; 179(3):291-6. PubMed ID: 20493536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids and psychosis.
    Sewell RA; Ranganathan M; D'Souza DC
    Int Rev Psychiatry; 2009 Apr; 21(2):152-62. PubMed ID: 19367509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis.
    van Winkel R; Kuepper R
    Annu Rev Clin Psychol; 2014; 10():767-91. PubMed ID: 24471373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids and psychosis.
    D'Souza DC
    Int Rev Neurobiol; 2007; 78():289-326. PubMed ID: 17349865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways to psychosis in cannabis abuse.
    Shrivastava A; Johnston M; Terpstra K; Bureau Y
    Clin Schizophr Relat Psychoses; 2015 Apr; 9(1):30-5. PubMed ID: 23491968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia.
    Arendt M; Mortensen PB; Rosenberg R; Pedersen CB; Waltoft BL
    Arch Gen Psychiatry; 2008 Nov; 65(11):1269-74. PubMed ID: 18981338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines.
    Kuepper R; Morrison PD; van Os J; Murray RM; Kenis G; Henquet C
    Schizophr Res; 2010 Aug; 121(1-3):107-17. PubMed ID: 20580531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism.
    Estrada G; Fatjó-Vilas M; Muñoz MJ; Pulido G; Miñano MJ; Toledo E; Illa JM; Martín M; Miralles ML; Miret S; Campanera S; Bernabeu C; Navarro ME; Fañanás L
    Acta Psychiatr Scand; 2011 Jun; 123(6):485-92. PubMed ID: 21231925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabis use, COMT, BDNF and age at first-episode psychosis.
    Mané A; Bergé D; Penzol MJ; Parellada M; Bioque M; Lobo A; González-Pinto A; Corripio I; Cabrera B; Sánchez-Torres AM; Saiz-Ruiz J; Bernardo M;
    Psychiatry Res; 2017 Apr; 250():38-43. PubMed ID: 28142064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis-associated psychosis: Neural substrate and clinical impact.
    Murray RM; Englund A; Abi-Dargham A; Lewis DA; Di Forti M; Davies C; Sherif M; McGuire P; D'Souza DC
    Neuropharmacology; 2017 Sep; 124():89-104. PubMed ID: 28634109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Laboratory Studies on Cannabinoids and Psychosis.
    Sherif M; Radhakrishnan R; D'Souza DC; Ranganathan M
    Biol Psychiatry; 2016 Apr; 79(7):526-38. PubMed ID: 26970363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia].
    Sewell RA; Skosnik PD; Garcia-Sosa I; Ranganathan M; D'Souza DC
    Braz J Psychiatry; 2010 May; 32 Suppl 1():S15-30. PubMed ID: 20512267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids and Psychosis.
    D'Souza DC; Radhakrishnan R; Sherif M; Cortes-Briones J; Cahill J; Gupta S; Skosnik PD; Ranganathan M
    Curr Pharm Des; 2016; 22(42):6380-6391. PubMed ID: 27568729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs of abuse and increased risk of psychosis development.
    Gururajan A; Manning EE; Klug M; van den Buuse M
    Aust N Z J Psychiatry; 2012 Dec; 46(12):1120-35. PubMed ID: 22833579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the Risks and Consequences of Adolescent Cannabis Exposure.
    Levine A; Clemenza K; Rynn M; Lieberman J
    J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):214-225. PubMed ID: 28219487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabis and psychosis: what is the link?
    Ben Amar M; Potvin S
    J Psychoactive Drugs; 2007 Jun; 39(2):131-42. PubMed ID: 17703707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects of cannabis.
    Prescrire Int; 2011 Jan; 20(112):18-23. PubMed ID: 21462790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Cannabis Use in People with Psychosis.
    Chesney E; Lawn W; McGuire P
    Cannabis Cannabinoid Res; 2024 Feb; 9(1):49-58. PubMed ID: 37971872
    [No Abstract]   [Full Text] [Related]  

  • 20. Cannabis, cannabinoids and schizophrenia: integration of the evidence.
    Cohen M; Solowij N; Carr V
    Aust N Z J Psychiatry; 2008 May; 42(5):357-68. PubMed ID: 18473254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.